Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease
Authors:
- Nicolás MerchanteNMNicolás Merchante
- José A Girón-GonzálezJosé A Girón-González
- Mercedes González-SerranoMGMercedes González-Serrano
- Julian Torre-CisnerosJTJulian Torre-Cisneros
- José A García-GarcíaJGJosé A García-García
- Ana ArizcorretaAAAna Arizcorreta
- Josefa Ruiz-MoralesJRJosefa Ruiz-Morales
- Pilar Cano-LliterasPCPilar Cano-Lliteras
- Fernando LozanoFLFernando Lozano
- Carmen Martínez-SierraCMCarmen Martínez-Sierra
- Juan MacíasJMJuan Macías
- Juan A PinedaJPJuan A Pineda
- 2 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (1) , 49-57
Abstract
To find the survival and the predictors of death of HIV-infected patients with hepatitis C virus (HCV)-related end-stage liver disease (ESLD). A prospective cohort study set in the infectious diseases units of four tertiary care public hospitals in Andalucía, Spain. From a multicentric cohort of 2664 HIV/HCV-co-infected patients, all consecutive patients with HCV-related cirrhosis who presented with the first hepatic decompensation from January 1997 to June 2004 were followed-up and 153 patients were included. The survival and the demographic, HIV-related and liver-related factors associated with death were evaluated. Ninety-five (62%) patients died during the follow-up. In 79 (85%) individuals, the cause of death was liver related. The median survival time was 13 months. Independent predictors of survival were Child score [hazard ratio (HR), 1.2; 95% confidence interval (CI), 1.08–1.37; P = 0.001], CD4+ cell count at decompensation lower than 100 cells/μl (HR, 2.48; 95% CI, 1.52–4.06; P < 0.001) and hepatic encephalopathy as the first hepatic decompensation (HR, 2.45; 95% CI, 1.41–4.27; P = 0.001). HAART was prescribed to 101 (66%) patients. The cumulative probability of survival in patients under HAART was 60% at 1 year and 40% at 3 years, versus 38 and 18%, respectively, in patients not treated with HAART (P < 0.0001). The HR (95% CI) of death in patients on HAART was 0.5 (0.3–0.9), (P = 0.03). The survival of HIV/HCV-co-infected patients with ESLD is extremely poor. Immunosuppression and markers of severe liver disease predict liver-related mortality in these patients. HAART seems to be associated with a reduced liver-related mortality.Keywords
This publication has 21 references indexed in Scilit:
- HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†Hepatology, 2005
- Survival in patients with HIV infection and viral hepatitis B or CAIDS, 2004
- Care of patients with hepatitis C and HIV co-infectionAIDS, 2004
- Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfectionThe Lancet, 2003
- Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patientsGut, 2003
- Progression of Chronic Hepatitis C to Liver Fibrosis and Cirrhosis in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency VirusClinical Infectious Diseases, 2003
- Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus ConferenceHIV Research & Clinical Practice, 2002
- Impact of Human Immunodeficiency Virus Infection on Progression to End‐Stage Liver Disease in Individuals with Hemophilia and Hepatitis C Virus InfectionThe Journal of Infectious Diseases, 2001
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patientsHepatology, 1999